Inflammatory Bowel Diseases, Ulcerative Colitis
Conditions
Brief summary
Ulcerative colitis (UC) is an incurable, immune-mediated inflammatory disease of the large bowel that typically requires long term immunosuppressive drugs to induce and maintain remission. Hospitalisation due to severe, uncontrolled disease is a common occurrence and estimated to affect up to 25% of UC patients. Janus kinase inhibitors (JAKi) have attracted considerable attention as potential candidates for treating hospitalised patients with severe UC and are increasingly used in this setting. For tofacitinib, there are accumulating data supporting their use as effective induction agents to prevent colectomy and reduce length of hospitalisation, however, these are limited to small case series and small cohort studies only. There are no published data for the use of filgotinib and upadacitinib for treating severe inpatient colitis. The aim of this study is to develop a large retrospective cohort of JAKi-treated hospitalised UC patients to describe the safety and effectiveness of using JAKi in this setting.
Interventions
None listed
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patient ≥ 18 years old, * Established diagnosis of ulcerative colitis as per ECCO (European Crohn´s and Colitis Organisation) criteria, * Hospitalisation at any point for treatment of ulcerative colitis disease relapse, * Receiving at least one dose of tofacitinib, filgotinib, or upadacitinib for the treatment of severe UC during inpatient stay, * Endoscopically confirmed active disease (Mayo endoscopic subscore ≥ 2) within previous four weeks, * Patient who has received full information about the organization of the research and who has not objected to his or her participation and to the use of his or her data.
Exclusion criteria
* Diagnosis of Crohn's disease or unclassified Inflammatory Bowel Disease, * Receiving JAKi prior to admission, * Clostridium difficile, cytomegalovirus (CMV), or other enteric infections identified on admission.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment failure up to day 98 after JAKi initiation to describe treatment effectiveness | after study completion, average of 1 month | * Absence of steroid-free clinical remission according to the PRO-2 (stool ≤1 and rectal bleeding sub-score of 0) * Use of a prohibited treatment for relapse (partial Mayo score \>5) * Severe adverse event leading to discontinuation of JAKi treatment * Colectomy * Death during the study period |
Countries
France
Outcome results
None listed